WTA reduces reading parameters and NVA

Article

With-the-rule astigmatism (WTA) reduces reading parameters and near visual acuity (NVA) compared with against-the-rule astigmatism (ATR) and no astigmatism, according to a recent paper.

With-the-rule astigmatism (WTA) reduces reading parameters and near visual acuity (NVA) compared with against-the-rule astigmatism (ATR) and no astigmatism, according to a recent paper.

Professor Thomas Kohnen et al., Department of Ophthalmology, Johann Wolfgang Goethe-University, Germany, conducted a consecutive case series on 23 eyes of 23 participants. All subjects were fogged with 0 D, −0.75 D and −1.5 D of ATR astigmatism via lenses with spherical compensation.

Every participant was cyclopleged and distance corrected The outcome measures included reading acuity (RAc), reading speed (RS) and NVA. Data was compared using the outcomes of Wilcoxon-matched-pairs test, regression analysis and Bland–Altman analysis.

Increasing the amount of astigmatism caused a decreased NVA and RAc, whereas WTR astigmatism caused a reduced NVA, RAc and RS compared to the results of ATR astigmatism.

Outcomes revealed that that NVA was better than RAc with no astigmatism, −0.75 D WTR and −1.5 D WTR. The study group did not observe any differences between NVA and RAc for −0.75 D ATR and −1.5 D ATR.

For more information on the study please visit the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.